MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 70 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $435,545 | -82.0% | 54,105 | -75.7% | 0.00% | -83.3% |
| Q2 2023 | $2,416,176 | +874.3% | 222,484 | +333.5% | 0.01% | +500.0% |
| Q2 2022 | $248,000 | +15.9% | 51,325 | +124.0% | 0.00% | 0.0% |
| Q1 2022 | $214,000 | -79.9% | 22,916 | -61.4% | 0.00% | -50.0% |
| Q2 2021 | $1,064,000 | +14.8% | 59,292 | -1.0% | 0.00% | 0.0% |
| Q1 2021 | $927,000 | +15.9% | 59,868 | -8.7% | 0.00% | 0.0% |
| Q4 2020 | $800,000 | +282.8% | 65,600 | +302.4% | 0.00% | +100.0% |
| Q3 2020 | $209,000 | – | 16,301 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |